Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Open-Label, Prospective, Multicenter Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human), IgPro20 in Subjects With Primary Immunodeficiency (PID)

NCT00419341 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT00419341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00419341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Open-Label, Prospective, Multicenter Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human), IgPro20 in Subjects With Primary Immunodeficiency (PID)
Lead sponsor
CSL Behring
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2006
Completion date
October 31, 2008
Enrollment
49 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

primary immune deficiency